Techno Trends
Worldwide advancements and breakthroughs in pharmaceutical products and technology are thoroughly covered by Techno Trends. You may stay up to date with all the most recent pharmaceutical developments (product news and technological trends) taking place throughout the world.
Mount Sinai Researchers Determine Significant Beta Cell Proliferation Using Combination of Pharmacologic and Genetic Inhibition
A major breakthrough in diabetes treatment has been achieved by researchers at Mount Sinai, who have combined pharmacologic and genetic inhibition to stimulate the proliferation of beta cells....
Novartis Promacta® Approved as First-Line Treatment for Severe Aplastic Anemia(SAA)
Novartis' Promacta® has received approval as the primary treatment option for Severe Aplastic Anemia (SAA) in both adults and pediatric patients aged two years and above. This approval is in combination with standard immunosuppressive therapy (IST)....
NRX-101 Represents New Class of Antidepressants to Decrease Suicidal Thoughts
<p>NeuroRx's NRX-101, the first oral drug targeting suicidal bipolar depression helps to treat severe bipolar depression with Acute Suicidal Ideation & Behavior (ASIB).</p> <p>NRX-101 is used for treatment of Severe Bipolar Depression with Acute Suicidal Ideation & Behaviour after initial stabilisation with ketamine or other effective therapy.</p> <p>NRX-101 (D-cycloserine/lurasidone fixed dose combination) is the first oral drug demon...
Researchers Design and Develop New Class of Molecules to Halt Tumors
Researchers at Stevens Institute of Technology and colleagues have designed and developed a new class of molecules that use a never-before-known mechanism that may halt or destroy breast cancer tumors....
Insmed Announces ARIKAYCE® For the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease
Insmed, Inc. has unveiled ARIKAYCE® (amikacin liposome inhalation suspension) as a breakthrough treatment for Mycobacterium Avium Complex (MAC) lung disease in adult patients...
NUS and Harvard Scientists Develop Novel Drug to Treat Liver Cancer Effectively
Scientists at the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have made a significant breakthrough in the treatment of liver cancer by developing a novel peptide drug called FFW....
Pfizer Launches Janus Kinase 3 (JAK3) Inhibitor PF-06651600
Pfizer launched its investigational oral Janus Kinase 3 (JAK3) inhibitor PF-06651600, which is used for the treatment of patients with alopecia areata. Alopecia areata is chronic autoimmune skin disease in which immune cells attack healthy hair...
Alnylam’s ONPATTRO to Treat Patients with Hereditary ATTR Amyloidosis in Adults
Our research focused on developing ion-pairing HPLC methods with UV detection for the precise determination of two widely used chelating agents: ethylenediaminetetraacetic acid (EDTA) in Abilify® oral solution and diethylenetriaminepentaacetic acid...
Encorafenib (BRAFTOVI™) to Treat Patients with BRAFV600E-Mutant Metastatic Colorectal Cancer (mCRC)
<p xss=removed>Encorafenib (BRAFTOVI™), in combination with binimetinib (MEKTOVI®) and cetuximab has been designed to treat patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).</p> <p xss=removed>BRAFV600E-mutant mCRC will be an important treatment option to the cancer patients in critical need.</p> <p xss=removed>The results were made from the safety lead-in of the ongoing randomised Phase 3 BEACON CRC trial showed that, at ...
Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Treats Relapsed/Refractory FLT3-ITD AML
<p xss=removed>Daiichi Sankyo Company, Limited announced quizartinib, an investigational FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD Acute Myeloid Leukemia (AML).</p> <p xss=removed>Quizartinib is the first FLT3 inhibitor to enhance overall survival as an oral, single agent compared to chemotherapy in patients with relapsed/refractory AML with FLT3-ITD, an underlying driver of this subtype of AML.</p> ...
